Biomarkers in Tumor Tissue Samples From Younger Patients With Rhabdomyosarcoma

Brief Title

Biomarkers in Tumor Tissue Samples From Younger Patients With Rhabdomyosarcoma

Official Title

Observational - CRKL Expression at the Protein Level in Rhabdomyosarcoma Tumors by Tissue Microarray (TMA)

Brief Summary

      This research trial studies biomarkers in tumor tissue samples from younger patients with
      rhabdomyosarcoma. Studying samples of tumor tissue from patients with cancer in the
      laboratory may help doctors learn more about changes that occur in DNA and identify
      biomarkers related to cancer
    

Detailed Description

      PRIMARY OBJECTIVES:

      I. To demonstrate CRKL expression at the protein level in rhabdomyosarcoma tumors by tissue
      microarray (TMA).

      OUTLINE:

      Archived tumor tissue samples are analyzed for CRKL expression.
    


Study Type

Observational


Primary Outcome

CRKL expression at the protein level


Condition

Alveolar Childhood Rhabdomyosarcoma

Intervention

laboratory biomarker analysis

Study Arms / Comparison Groups

 Basic science (biomarker analysis)
Description:  Archived tumor tissue samples are analyzed for CRKL expression.

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Other

Estimated Enrollment

77

Start Date

December 2011

Completion Date

May 2016

Primary Completion Date

May 2016

Eligibility Criteria

        Inclusion Criteria:

          -  Alveolar rhabdomyosarcoma and embryonal rhabdomyosarcoma specimens from the Children
             Oncology Group (COG) tumor microarrays (TMAs)
      

Gender

All

Ages

N/A - N/A

Accepts Healthy Volunteers

No

Contacts

Lee Helman, MD, , 

Location Countries

United States

Location Countries

United States

Administrative Informations


NCT ID

NCT01496573

Organization ID

ARST12B4

Secondary IDs

NCI-2012-00094

Responsible Party

Sponsor

Study Sponsor

Children's Oncology Group

Collaborators

 National Cancer Institute (NCI)

Study Sponsor

Lee Helman, MD, Principal Investigator, Children's Oncology Group


Verification Date

May 2016